{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:51Z","timestamp":1787239971091,"version":"build-2736575974"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Die Immunthrombozytopenie wird durch Autoantik\u00f6rper gegen Pl\u00e4ttchen-Oberfl\u00e4chenantigene ausgel\u00f6st. Da der Nachweis von glykoproteinspezifischen Antik\u00f6rpern nur in etwa der H\u00e4lfte der F\u00e4lle gelingt, bleibt die ITP eine Ausschlussdiagnose. Neben der EDTA-induzierten Pseudothrombozytopenie m\u00fcssen insbesondere die sekund\u00e4re medikament\u00f6se Thrombozytopenie, eine breite Palette anderer Erkrankungen und heredit\u00e4re Thrombozytopenien bedacht werden. In der Therapie der ITP sind Kortikosteroide und Immunglobuline Mittel der Wahl in der Erstlinie. Die Zweitlinie umfasst Thrombopoetin-Rezeptor-Agonisten, Rituximab oder die Splenektomie. Danach kommen der Einsatz von Fostamatinib und nicht steroidaler Immunsuppressiva in Betracht.<\/jats:p>","DOI":"10.1055\/a-2277-2059","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T18:55:18Z","timestamp":1721156118000},"page":"895-903","source":"Crossref","is-referenced-by-count":1,"title":["Differenzialdiagnose und Therapie der Immunthrombozytopenie"],"prefix":"10.1055","volume":"149","author":[{"given":"Aristoteles","family":"Giagounidis","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Onkologie und Palliativmedizin, Marien-Hospital D\u00fcsseldorf, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1515\/labmed-2023-0032","article-title":"EDTA-associated pseudothrombocytopenia: definition and real-world occurrence","volume":"47","author":"R Markewitz","year":"2023","journal-title":"Journal of Laboratory Medicine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094521","article-title":"Inherited Platelet Disorders: An Updated Overview","volume":"22","author":"V Palma-Barqueros","year":"2021","journal-title":"International journal of molecular sciences"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3324\/haematol.2010.039883","article-title":"Bernard-Soulier syndrome","volume":"96","author":"M C Berndt","year":"2011","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1182\/blood-2017-06-742692","article-title":"How I treat type 2B von Willebrand disease","volume":"131","author":"R Kruse-Jarres","year":"2018","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/bf01720508","article-title":"Hereditary types of thrombocytopenia with giant platelets and inclusion bodies in the leukocytes","volume":"60","author":"A Greinacher","year":"1990","journal-title":"Blut"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/tacg.s58444","article-title":"Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments","volume":"7","author":"D Buchbinder","year":"2014","journal-title":"The application of clinical genetics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ijlh.12999","article-title":"Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia","volume":"41","author":"P Galera","year":"2019","journal-title":"International Journal of Laboratory Hematology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose Dexamethasone","volume":"349","author":"Y Cheng","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/0090-1229(89)90080-9","article-title":"The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura","volume":"53","author":"J B Bussel","year":"1989","journal-title":"Clinical immunology and immunopathology"},{"key":"ref10","first-page":"961","article-title":"Intravenous immunoglobulin therapy for refractory chronic idiopathic thrombocytopenic purpura","volume":"136","author":"J R Leclerc","year":"1987","journal-title":"CMAJ: Canadian Medical Association journal = journal de l\u2019Association medicale canadienne"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"9992086","DOI":"10.1155\/2021\/9992086","article-title":"The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis","volume":"2021","author":"Y Dong","year":"2021","journal-title":"BioMed Research International"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/dddt.s299591","article-title":"A Review of Romiplostim Mechanism of Action and Clinical Applicability","volume":"15","author":"J B Bussel","year":"2021","journal-title":"Drug design, development and therapy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"G Cheng","year":"2011","journal-title":"The Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: A Review in Thrombocytopenia","volume":"81","author":"A Markham","year":"2021","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"N T Connell","year":"2019","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia","volume":"385","author":"C A Bradbury","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The Effect of Danazol in Primary Immune Thrombocytopenia: An Analysis of a Large Cohort From a Single Center in China","volume":"22","author":"W Liu","year":"2016","journal-title":"Clinical and applied thrombosis\/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/jth.12371","article-title":"Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review","volume":"11","author":"C Rodrigo","year":"2013","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/09537104.2020.1738367","article-title":"Revisiting the management of chronic ITP; a randomized controlled clinical trial","volume":"32","author":"G EM Abdallah","year":"2021","journal-title":"Platelets"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2141.2001.02893.x","article-title":"Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy","volume":"114","author":"M C Kappers-Klunne","year":"2001","journal-title":"Br J Haematol"},{"key":"ref21","volume-title":"Physiologic and Pharmacologic Effects of Corticosteroids. 6th Edition. Aufl. Hamilton","author":"L I McKay","year":"2003"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/s2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"S Mithoowani","year":"2016","journal-title":"The Lancet Haematology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1423-0410.2002.tb05268.x","article-title":"Mechanism of action of IVIG in ITP","volume":"83","author":"A H Lazarus","year":"2002","journal-title":"Vox Sanguinis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncprheum0424","article-title":"Drug Insight: the mechanism of action of rituximab in autoimmune disease \u2013 the immune complex decoy hypothesis","volume":"3","author":"R P Taylor","year":"2007","journal-title":"Nature Clinical Practice Rheumatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.revmed.2020.05.016","article-title":"Rituximab and immune thrombocytopenia in adults: The state of knowledge 20 years later","volume":"42","author":"S Deshayes","year":"2021","journal-title":"La Revue de medecine interne"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5\u200ayears from the French prospective registry ITP-ritux","volume":"94","author":"S Deshayes","year":"2019","journal-title":"American journal of hematology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1316096","DOI":"10.1155\/2018\/1316096","article-title":"Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis","volume":"2018","author":"J Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/09537104.2021.1925102","article-title":"The thrombopoietin receptor: revisiting the master regulator of platelet production","volume":"32","author":"I S Hitchcock","year":"2021","journal-title":"Platelets"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"D J Kuter","year":"2022","journal-title":"Blood reviews"},{"key":"ref30","first-page":"A-334","article-title":"Arzneimitteltherapiesicherheit: Das Interaktionspotenzial der Basisantirheumatika","volume":"115","author":"H Petri","year":"2018","journal-title":"Dtsch Arztebl"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"S Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/blood-2015-03-632000","article-title":"How does dapsone work in immune thrombocytopenia? Implications for dosing","volume":"125","author":"Q A Hill","year":"2015","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/jrpp.JRPP_17_60","article-title":"The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature","volume":"7","author":"F Mohammadpour","year":"2018","journal-title":"Journal of research in pharmacy practice"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3238\/arztebl.2014.0809","article-title":"Platelet transfusion in hematology, oncology and surgery","volume":"111","author":"H Wandt","year":"2014","journal-title":"Deutsches Arzteblatt international"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"F Zaja","year":"2010","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"S Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"M Khellaf","year":"2013","journal-title":"Haematologica"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study","volume":"197","author":"H Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040659","article-title":"Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme","volume":"59","author":"T J Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/17474086.2021.1995347","article-title":"Immune thrombocytopenia","volume":"14","author":"J Bussel","year":"2021","journal-title":"Expert review of hematology"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2277-2059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:56:26Z","timestamp":1730804186000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2277-2059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":40,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2277-2059","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]}}}